Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight/obesity
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate the effect of beinaglutide on weight loss and plasma protein patterns of inflammation/obesity relevant cytokines and biomarkers. METHODS: and T2DM. Beinaglutide was administered for three months. Changes in body weight, fasting plasma glucose (FPG) level, 2 h postprandial plasma glucose (2h-PG) level, glycosylated hemoglobin (HbA1c) level, BMI and visceral and subcutaneous fat areas were measured at baseline and after three months of treatment. In addition, relevant inflammation/obesity cytokines and biomarkers were measured. RESULTS: After three months, beinaglutide treatment led to significant changes, including in body weight, BMI, FPG level, HbA1c level, visceral and subcutaneous fat areas. In addition, serpin E1, leptin, C-reaction protein (CRP) and tumor necrosis factor-α (TNF-α) also decreased significantly. The plasma protein concentrations of CRP (Log2 transformed) were found to be positively correlated with the percentage of weight loss (R = 0.514 and p-value = 0.021). CONCLUSION: Beinaglutide treatment resulted in weight loss, plasma glucose control and anti-inflammatory effects in patients with T2DM and overweight/obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In clinical studies, Wang (41) et al. included 36 patients (T2DM) with BMI ≥ 24 kg/m2. After treatment with BN for 3 months, BMI, fasting blood glucose, glycosylated hemoglobin, visceral and subcutaneous fat, silk protein E1, leptin, C-reactive protein (CRP), and tumor necrosis factor decreased significantly; the level of CRP is related to the weight loss percentage treated with BN.”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serum Immunoreactive-Leptin Concentrations in Normal-Weight and Obese Humans
Considine, R. V., Sinha, M. K., Heiman, M. L., Kriauciunas, A., Stephens, T. W., Nyce, M. R., Ohannesian, J. P., Marco, C. C., McKee, L. J., Bauer, T. L., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602013340503 · Cited by 6,326 · cited 1×
“The serum leptin level in patients with obesity was higher than that in the normal weight group, and a decrease in body weight led to a decrease in leptin levels (27,28).”
Prospective Studies Collaboration (2009) · The Lancet · doi:10.1016/s0140-6736(09)60318-4 · Cited by 4,807
Selected major risk factors and global and regional burden of disease
Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S., & Murray, C. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11403-6 · Cited by 3,594
Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome
Wajchenberg, B. L. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0415 · Cited by 2,961 · cited 1×
“Abdominal visceral fat and subcutaneous fat are independent risk factors for cardiovascular diseases and metabolic syndrome (18,19).”
Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index
Gallagher, D., Heymsfield, S. B., Heo, M., Jebb, S. A., Murgatroyd, P. R., & Sakamoto, Y. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.694 · Cited by 2,139 · cited 1×
“Obesity has been recognized as one of the greatest public health concerns worldwide, especially in developed countries (1).”
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement
Neeland, I. J., Ross, R., Després, J.-P., Matsuzawa, Y., Yamashita, S., Shai, I., Seidell, J., Magni, P., Santos, R. D., Arsenault, B., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30084-1 · Cited by 1,603
The Emerging Risk Factors Collaboration (2011) · The Lancet · doi:10.1016/s0140-6736(11)60105-0 · Cited by 1,216
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Therefore, the results of this study indicate the advantages of beinaglutide as a GLP-1 homolog with 100% protein sequence identity to human natural GLP-1 and short half-life (30 min) (16,17).”
National, regional, and global trends in adult overweight and obesity prevalences
Stevens, G. A., Singh, G. M., Lu, Y., Danaei, G., Lin, J. K., Finucane, M. M., Bahalim, A. N., McIntire, R. K., Gutierrez, H. R., Cowan, M., et al. (2012) · Population Health Metrics · doi:10.1186/1478-7954-10-22 · Cited by 929 · cited 11×
“It has been reported that leptin decreased after treatment with diet control or GLP-1 drugs in patients with T2DM with effective or ineffective weight loss (25,26).”
InfluentialGlucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · cited 1×
“Several GLP-1 receptor agonists (GLP-1RA) have been promoted for the treatment of T2DM and have multiple potential effects on hyperglycaemia, cardiovascular and liver disease (9,10).”
Cited by
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Anti‐diabetic drugs and sarcopenia: emerging links, mechanistic insights, and clinical implications
Zhang, X., Zhao, Y., Chen, S., & Shao, H. (2021) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12838 · Cited by 92
“Several studies have reported that GLP-1 or GLP-1 analogues can cause weight loss in animals and humans.(53,54) The mechanisms are likely attributed to decreased energy intake (e.”
BackgroundA narrative review of approved and emerging anti-obesity medications
Abdi Beshir, S., Ahmed Elnour, A., Soorya, A., Parveen Mohamed, A., Sir Loon Goh, S., Hussain, N., Al Haddad, A. H. I., Hussain, F., Yousif Khidir, I., & Abdelnassir, Z. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101757 · Cited by 51
“The trial NCT04251156 (Nordisk A/S, 2023b), evaluated the impact of a once-weekly injection of semaglutide 2.4 mg compared to a placebo in 375 over-weight or obese participants with or without T2DM from China, the Republic of Korea, and Brazil.”
InfluentialUnlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“Several biomarkers showed a marked decline after three months of Beinaglutide treatment, including BMI, fasting blood glucose (FBG), glycated hemoglobin (HbA1c), visceral and subcutaneous fat, leptin, C-reactive protein, and tumor necrosis factor (TNF) [217].”
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Gong, B., Yao, Z., Zhou, C., Wang, W., Sun, L., & Han, J. D. J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116342 · Cited by 29
Lin, P., Li, C., Liu, Y., Sun, F., Hsieh, T.-H., Zhang, L., Ma, Y., Gao, X., Yu, Q. T., & Cao, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1433587 · Cited by 9
“In addition, multiple studies (Nadkarni et al., 2014; Zhang et al., 2019; Wang et al., 2021) have shown that beinaglutide may signi fi cantly reduce the weight of T2DM patients by delaying gastric emptying and reducing food intake.”
BackgroundLiu, X., Yang, W., Liu, J., Huang, X., Fang, Y., Ming, J., Lai, J., Fu, J., Ji, Q., & Wang, L. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13483 · Cited by 8
“20 20,21 Beinaglutide is also able to improve vascular endothelial function.”
BackgroundHan, C.-Y., Ye, X., Lu, J.-P., Jin, H., Wang, P., Xu, W., & Zhang, M. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s418757 · Cited by 7
Han, C.-Y., Lu, J.-P., Ye, X.-M., Jin, H., Xu, W., Wang, P., & Zhang, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1267503 · Cited by 5
“The dosage may be increased to 0.2 mg tid if the glycemic response is inadequate (17).”
BackgroundInfluentialKamrul-Hasan, A. B. M., Ganakumar, V., Nagendra, L., Dutta, D., Islam, M. R., & Pappachan, J. M. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i5.103244 · Cited by 4
Research Progress on Peptide Drugs for Type 2 Diabetes and the Possibility of Oral Administration
Yang, X., Lin, R., Feng, C., Kang, Q., Yu, P., Deng, Y., & Jin, Y. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111353 · Cited by 6
Luo, Y., Ding, B., Xia, W., Liu, B., Ge, S., Lü, Y., & Ma, J. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02665-7 · Cited by 1
“Moreover, previous clinical trials have demonstrated that the dose-dependent effects of beinaglutide both in efficacy and gastrointesti - nal side effects [25 , 26 , 41 ].”
Micah Isaac Anand, W. (2023) · International Journal of Science and Research (IJSR) · doi:10.21275/sr23516191456
“Several studies have reported that GLP - 1 or GLP 1 analogues can cause weight loss in animals and humans [75, 76].”
BackgroundXu, Y., Velu, P., Hu, L., & Guimarães, N. S. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01633-8
“Beinaglutide, a novel GLP-1RA, has garnered attention for its potential to improve cardiometabolic parameters by modulating glucose metabolism, reducing body weight, and exerting favorable effects on blood pressure and lipid profiles [10, 11].”
Poshtdar, S., Rohani, P., Ahrabi, A., Panahi, N., & Sohouli, M. H. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2491404
“Beinaglutide has been shown to effectively lower the levels of inflammatory cytokine TNF-α and C-reactive protein (CRP), as a significant inflammation associated biomarker, highly linked to pathogenesis of diseases such as diabetes and cardiovascular diseases [21–23].”
Wen, J., Truong, A., Nadora, D., How-Volkman, C., Bernstein, E. M., Kou, M., Alam, A., Puglisi, J. L., & Frezza, E. (2025) · Cureus · doi:10.7759/cureus.100224
“Additional heterogeneity with dietary and lifestyle modifications was also observed [18,19].”
Optimizing GLP-1 Receptor Agonist Use: Mechanisms, Clinical Applications, and Safety Profiles
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8391-3
Chen, Z., Zhou, Y., Li, G., MUTHANNA, A., d’Arqom, A., Tham, C. L., Ho, Y.-C., & Lee, M. T. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02110-3
“Long-term studies revealed no risks of pancreatitis, cholelithiasis, or psychiatric adverse events (e.g., depression, suicidality), and the drug showed no genetic or reproductive tox - icity [153, 156–158 ].”
Metadata
- Authors
- Wang, G., Wu, P., Qiu, Y., Dong, X., Wang, Y., Chi, Y., Zhang, F., Li, Y., Zhang, J., Huang, Z., Du, X., & Du, Z.
- Affiliations
- Shanxi Datong University (CN)
- Corresponding author
- Du, Zhiqiang
- ORCID
- Venue
- Archives of Endocrinology and Metabolism
- Published
- 2021-07-16
- Volume
- 65
- Issue
- 4
- Pages
- 421-427
- ISSN
- 2359-3997 (ISSN-L)
- 2359-4292
- PMC
- PMC10522179
- OpenAlex
- W3185604417
- Cited by
- 17
- References
- 30
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 3 · 2023: 6 · 2021: 1
- FWCI
- 1.87
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Archives of Endocrinology and Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, obesity, weight loss, glycemic control, inflammation, C-reactive protein, TNF-α, leptin, SERPINE1, visceral fat, subcutaneous adipose tissue, HbA1c, Chinese patients
- MeSH terms
- Adult, Blood Glucose, China, Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Body Mass Index, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.